Iressa (Gefitinib)

Gefitinib is a type of medicine used to treat certain kinds of lung cancer. It works by blocking a protein called EGFR, which helps cancer cells grow. It's often used for lung cancer that has spread to other parts of the body. It's important to take this medicine exactly as prescribed by your doctor.

Brand names:Iressa
Medication

What people taking Iressa (Gefitinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Iressa (Gefitinib) for Non-Small Cell Lung Cancer?

NameHow it went

About Iressa (Gefitinib)

What It's For

Gefitinib, sold under the brand name Iressa and also available as a generic, is a targeted cancer pill for non-small cell lung cancer, the most common type of lung cancer. It is approved as a first treatment for cancer that has spread beyond the lung (metastatic) when the tumor carries one of two specific changes in a gene called EGFR (epidermal growth factor receptor): an exon 19 deletion or an exon 21 L858R mutation. That genetic requirement is the deciding factor. Before gefitinib is prescribed, a sample of the tumor, or sometimes a blood sample, is tested for these mutations with an approved test. If the blood test finds nothing, testing the tumor tissue is recommended when possible. Gefitinib has not been shown to work for lung cancers without these two mutations, including those with other, less common EGFR changes. Gefitinib is one of several drugs in this family. Osimertinib (Tagrisso), a newer EGFR-targeting pill, kept cancer under control longer and helped people live longer than gefitinib or a similar older drug, erlotinib, when used as a first treatment in a large trial. That result is one reason an oncologist may recommend a different option, so the choice is worth discussing.

How It Works

EGFR is a receptor on the surface of cells that relays signals telling the cell to grow and divide. In some lung cancers, a mutation in the EGFR gene leaves this receptor switched on, so it keeps pushing the cancer cells to multiply and survive. Gefitinib blocks the part of the receptor that passes the signal into the cell, a type of enzyme called a tyrosine kinase. That is why it is called a tyrosine kinase inhibitor. It attaches more strongly to the mutated forms of EGFR than to the normal form, which is why the drug works best in tumors that depend on those mutations. Because healthy skin and the lining of the gut also rely on EGFR, blocking it there explains why rash and diarrhea are the most common side effects.

Dosage & Administration

Gefitinib is a tablet taken by mouth once a day, with or without food, ideally around the same time each day. The standard dose is the same for most people, and it is continued for as long as it keeps the cancer under control and the side effects are manageable. For people who have trouble swallowing, the tablet can be dropped into a glass of plain, non-carbonated water (about half a cup to a cup), stirred for about 15 minutes until it dissolves and drunk right away. Rinsing the glass with the same amount of water and drinking that too makes sure the full dose is taken. The dissolved tablet can also be given through a feeding tube. If a dose is missed, it can be taken when remembered unless the next dose is due in less than 12 hours; in that case, skip it and take the next one as usual rather than doubling up. The care team may pause treatment for a while, or stop it, if certain side effects develop.

Side Effects

Skin reactions are the most common side effect, affecting nearly half of people in studies. They include an acne-like rash, dry or itchy skin and sometimes nail problems such as irritated, infected skin around the nails. Diarrhea is the next most common, affecting about 3 in 10 people. Mouth sores, nausea, loss of appetite and tiredness can also occur. Dry, red or irritated eyes are possible, and unusual eyelash growth has been reported. Most of these can be managed with skin care, anti-diarrhea medicine or a short pause in treatment, so it helps to report them early rather than wait. A few reactions need prompt attention. New or worsening shortness of breath, cough or fever can be a sign of lung inflammation (interstitial lung disease), which is uncommon but can be serious; contact the care team right away so the drug can be paused and the cause checked. Also call promptly for severe or ongoing diarrhea, eye pain or redness, sensitivity to light or changes in vision, and signs of liver trouble such as yellowing of the skin or eyes or dark urine. Severe belly pain, which can rarely signal a tear in the stomach or intestine, and blistering or peeling skin need medical care right away.

Interactions & Warnings

Medicines that reduce stomach acid can lower the amount of gefitinib the body absorbs. Proton pump inhibitors, such as omeprazole (Prilosec) and pantoprazole (Protonix), are best avoided; if one is needed, gefitinib should be taken 12 hours apart from it. Antacids and H2 blockers (another type of acid reducer) such as famotidine (Pepcid) should be taken at least 6 hours before or after gefitinib. Some medicines change how quickly the liver breaks gefitinib down. Strong enzyme-boosting drugs, such as the antibiotic rifampin and the seizure medicine phenytoin, can lower its levels enough that the prescriber may raise the dose. Strong enzyme-blocking drugs, such as the antifungals ketoconazole and itraconazole, can raise its levels and side effects. People taking the blood thinner warfarin need more frequent INR checks (a blood test of how fast blood clots), because higher readings and bleeding have been reported. Review all medicines and supplements with the oncologist and pharmacist before starting. Gefitinib can harm a developing baby and may increase the risk of pregnancy loss. Effective birth control is advised during treatment and for at least two weeks after the last dose, and breastfeeding should stop during treatment. Let the care team know about any history of lung scarring or other lung disease, eye problems or liver disease before starting.

What to Expect

Treatment is ongoing rather than a fixed course. Scans are repeated at intervals to see whether the cancer is shrinking or stable, and liver blood tests are checked periodically. Many tumors with these mutations shrink noticeably; in the main study about half did so by independent review, though complete disappearance was rare. Gefitinib controls the cancer for a period rather than curing it. In studies, the cancer was typically held in check for around 10 to 11 months on average before it began growing again, and the time varies widely between people. When the cancer progresses, the oncologist will usually look at what has changed, sometimes with another biopsy or blood test, to choose the next treatment. Side effects tend to be most noticeable in the first weeks. Many people continue their usual activities while taking it, and keeping the care team informed about skin, bowel, eye and breathing changes allows problems to be handled early.

Questions to Ask Your Doctor

  1. 1.Which EGFR mutation does my tumor have, and how was it confirmed?
  2. 2.Why do you recommend gefitinib for me rather than osimertinib or another option?
  3. 3.How will we know whether it is working, and how often will I have scans and blood tests?
  4. 4.How should I manage rash or diarrhea, and at what point should I call you?
  5. 5.If the cancer starts growing again, what testing and treatment would come next?

Last reviewed • Oct 2026

Educational content, not medical advice.